← Back to Search

Immunosuppressant

To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris

Phase 1 & 2
Waitlist Available
Led By James Krueger, MD, PHD
Research Sponsored by Rockefeller University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Approved for 20 Other Conditions
No Placebo-Only Group

Summary

This study compares the efficacy and analyzes the cellular effects of anti-TAC (Daclizumab) and Cyclosporine in the treatment of psoriasis vulgaris. This is a three-armed study-Daclizumab alone, Cyclosporine alone, and the combination of both Daclizumab and Cyclosporine.

Eligible Conditions
  • Psoriasis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

Approved for 20 Other Conditions
This treatment demonstrated efficacy for 20 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Cyclosporine and anti-TACExperimental Treatment1 Intervention
DaclizumabTM at 1mg/kg plus low dose cyclosporine (2 mg/kg/day)
Group II: cyclosporineActive Control1 Intervention
oral medication 2mg/kg/day orally from Day 0 until Day 90
Group III: anti-TACActive Control1 Intervention
1mg/kg/dose medication every other week on the odd week (week 1-13)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Daclizumab
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Rockefeller UniversityLead Sponsor
160 Previous Clinical Trials
16,506 Total Patients Enrolled
8 Trials studying Psoriasis
132 Patients Enrolled for Psoriasis
Facet BiotechIndustry Sponsor
21 Previous Clinical Trials
1,477 Total Patients Enrolled
1 Trials studying Psoriasis
6 Patients Enrolled for Psoriasis
James Krueger, MD, PHDPrincipal InvestigatorRockefeller University
1 Previous Clinical Trials
6 Total Patients Enrolled
1 Trials studying Psoriasis
6 Patients Enrolled for Psoriasis
~1 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top